The discussion highlights the pressures within the FDA, where funding stipulations prioritize drug approvals over post-marketing safety concerns. Careerism plays a significant role, as many professionals transition to lucrative positions in the pharmaceutical sector, often leading to a culture of complacency. This systemic issue reflects a broader trend in regulatory bodies worldwide, where individuals prioritize job security over accountability.
